title: Hormonal secretion and quality of life in Nelson syndrome and Cushing disease after long acting repeatable octreotide: a short series and update.
abstract: Clinical management of persistent adrenocorticotropin hormone (ACTH) excess in Nelson syndrome (NS) and Cushing disease (CD) remains a challenge. Somatostatin and its analogs as octreotide decrease ACTH secretion through somatostatin receptors of pituitary cells. To our knowledge, there are no reports on the effect of long-acting repeatable octreotide (oct-lar) on hormonal secretion and quality of life in patients with NS and CD who failed conventional therapy. Herein, we describe the effects of treatment with oct-lar (20 mg/month intramurally) in 1 woman with NS and 2 women with persistent CD. Oct-lar therapy reduced ACTH secretion and improved the quality of life in NS patient. By contrast, in CD patients, it failed to control ACTH and cortisol secretion, and the quality of life remained unchanged.
authors: 1Endocrine Research Department, Instituto de Investigaciones Médicas Alfredo Lanari, University of Buenos Aires; 2IDIM-CONICET and 3Salivary Glands Laboratory, University of Buenos Aires, Buenos Aires, Argentina.
authors: Alejandro L
authors: AL
authors: Arregger
authors: Estela M L
authors: EM
authors: Cardoso
authors: Olga B
authors: OB
authors: Sandoval
authors: Elida G
authors: EG
authors: Monardes Tumilasci
authors: Rocío
authors: R
authors: Sanchez
authors: Liliana N
authors: LN
authors: Contreras
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D008875:Middle Aged; D009347:Nelson Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D047748:Pituitary ACTH Hypersecretion / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D000324:Adrenocorticotropic Hormone; D015282:Octreotide; D006854:Hydrocortisone